Source:http://linkedlifedata.com/resource/pubmed/id/12591737
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2003-2-19
|
pubmed:abstractText |
Mutations of p53 gene occur in approximately 50% of human cancers, and accumulated p53 protein may be an appropriate target molecule to use for cancer immunotherapy. Indeed, mutated or nonmutated p53-derived peptides can induce HLA class I-restricted and tumor cell-reactive CTLs in vitro. However, to our knowledge, evidence that p53-derived peptides are truly recognized by CTLs at tumor sites has not yet been obtained. This study revealed that a mutated p53 gene encoded a nonmutated nonapeptide recognized by a HLA-B46-restricted and tumor cell-reactive CTL line that was established from T cells infiltrating a colon cancer lesion with the p53 mutation. This p53 peptide, at amino acid positions 99-107, had the ability to induce HLA-B46-restricted and peptide-specific CTLs reactive to tumor cells with the p53 mutation from the peripheral blood mononuclear cells of cancer patients, but not from those of healthy donors. These peptide-induced CTLs did not react to either HLA-B46(+) tumor cells without the p53 mutation or to HLA-B46(+) phytohemagglutinin-blastoid cells. These results provide a scientific basis for the development of p53-directed specific immunotherapy for HLA-B46(+) cancer patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes, T-Lymphocyte,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-B*46:01 antigen,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-B Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0008-5472
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
63
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
854-8
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:12591737-Animals,
pubmed-meshheading:12591737-COS Cells,
pubmed-meshheading:12591737-Cercopithecus aethiops,
pubmed-meshheading:12591737-Epitopes, T-Lymphocyte,
pubmed-meshheading:12591737-Female,
pubmed-meshheading:12591737-Genes, p53,
pubmed-meshheading:12591737-HLA-B Antigens,
pubmed-meshheading:12591737-Humans,
pubmed-meshheading:12591737-Lymphocyte Activation,
pubmed-meshheading:12591737-Male,
pubmed-meshheading:12591737-Neoplasms,
pubmed-meshheading:12591737-Peptide Fragments,
pubmed-meshheading:12591737-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:12591737-Transfection,
pubmed-meshheading:12591737-Tumor Cells, Cultured,
pubmed-meshheading:12591737-Tumor Suppressor Protein p53
|
pubmed:year |
2003
|
pubmed:articleTitle |
Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site.
|
pubmed:affiliation |
Department of Immunology, Kurume University School of Medicine, Kurume 830-0011, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|